Wolfe Research has increased its price target for Gilead Sciences (NASDAQ:GILD) to $170.00 from $155.00, maintaining an Outperform rating. This adjustment is based on the strong performance of Gilead’s HIV franchise in 2025, including the significant growth of Descovy and successful launch of Yeztugo. Despite potential headwinds from US policy impacts, the firm anticipates robust growth from key HIV products, while analysts forecast Gilead to be profitable in fiscal 2026 with an EPS of $8.76.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Gilead Sciences stock price target raised to $170 from $155 at Wolfe Research
Wolfe Research has increased its price target for Gilead Sciences (NASDAQ:GILD) to $170.00 from $155.00, maintaining an Outperform rating. This adjustment is based on the strong performance of Gilead’s HIV franchise in 2025, including the significant growth of Descovy and successful launch of Yeztugo. Despite potential headwinds from US policy impacts, the firm anticipates robust growth from key HIV products, while analysts forecast Gilead to be profitable in fiscal 2026 with an EPS of $8.76.